You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Using single-cell RNA-seq and other approaches, researchers looked at the four known medulloblastoma subtypes and the brain cell types from which they arise.
The company is aiming to create a suite of products that can help researchers and manufacturers engineer various genomes at scale for multiple purposes.
Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.
The team evaluated various technologies in an attempt to develop a framework to compare future methods against and to serve as a guide for researchers.
New methods for spatial transcriptomic profiling include a sequential FISH-based method and one that makes use of DNA-barcoded bead arrays.
The method builds on a previous technique the group developed to measure transcriptomes and surface proteins from single cells.
Some of the mutational signatures the researchers observed were similar to ones previously seen in B cell tumors, underscoring the link between aging and cancer.
Both teams had sequencing data generated at BGI and said that going forward, it would be important to validate the technology outside of BGI.
LabCorp's Covance business plans to offer single-cell services on Mission Bio's platform to pharma and to explore its use in companion diagnostics.
The effort, outlined in a Development Cell paper published online today, aims to complement the ongoing Human Cell Atlas initiative, but with a focus on pediatric health.
An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.
Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.
In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.
The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.